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Abstract 
Heart failure (HF) is a highly prevalent disease state world-
wide that can progress into a disabling condition. It is perti-
nent to have a treatment regimen that is effective in lowering 
the number of HF exacerbations and, therefore, hospital re-
admission rates. A novel medication currently in clinical tri-
als, LCZ696, blocks both neprilysin and angiotensin type I 
receptors. The overall effects are an inhibition of the break-
down of natriuretic peptides which leads to a decrease in 
renin and aldosterone release. This, combined with the 
antagonization of angiotensin type I receptors, leads to a 
decrease in blood pressure, blood volume and systemic vas-
cular resistance. The PARAMOUNT trial compared the thera-
peutic effectiveness of LCZ696 to valsartan monotherapy. 
This study demonstrated that patients taking LCZ696 had 
better improvements in symptoms and biomarkers. The 
PARADIGM-HF trial compared LCZ696 to enalapril. LCZ696 
showed significant reductions in cardiac death, hospitaliza-
tions and HF symptoms over enalapril. Although this new 
medication looks promising as a future treatment option for 
HF patients, additional studies should be completed to look 
at the long-term patient outcomes associated with LCZ696. 
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Introduction 
Cardiovascular disease has been the number one cause of 
death in the United States almost every year since 1935.1 
Heart failure (HF), characterized by a lack of blood perfusion 
due to decreased cardiac output, is a debilitating condition 
worldwide. Fortunately, through extensive drug develop-
ment, scientists and clinicians have been able to slow 
the decline of cardiac function. Currently, angiotensin-
converting-enzyme inhibitors (ACE-I) are the first line thera-
py options for HF patients based on recommendations from 
the 2013 American College of Cardiology Foundation/ 
American Heart Association guidelines .2 They are effective in 
preserving Left Ventricular Ejection Fraction (LVEF) and de-
creasing hypertension symptoms associated with HF. 
Table 1. ACCF /AHA Stages of HF.2 
ACCF /AHA Stages of HF 
However, recent research points to a novel approach in bet-
ter managing HF. In clinical trials, LCZ696, a dual neprilysin 
and angiotensin blocker, has consistently demonstrated clini-
cal effectiveness in many cardiac parameters. Future studies 
need to be conducted before LCZ696 is introduced into the 
market and incorporated into the guidelines as an alternative 
option to ACE-I, the current mainstay treatment for HF. 
Epidemiology 
With a prevalence of more than 5.8 million people in the 
United States and 23 million people worldwide, HF is a seri-
ous public health concern.3 Each year, there are more than 
550,000 new cases diagnosed in the United States 
alone. Heart failure prevalence is highest among black and 
Hispanic populations.2 Male and female populations have a 
similar incidence and prevalence of HF. However, women 
more commonly develop HF later in life and tend to survive 
longer with the disease than men. Even though HF can occur 
at any age, the prevalence is only about 1 to 2 percent in pop-
ulations younger than 55 years of age and increases to ap-
proximately 10 percent in populations over 75 years of age. 
Heart failure is a complicated clinical syndrome that is the 
consequence of a structural or functional cardiac disorder. It 
results in an impaired ability of the heart to pump blood suf-
ficiently enough to meet the requirement of metabolizing 
tissues.2-3 There are different types of HF which may result in 
various outcomes. Left-sided HF can cause fluid backup in 
the lungs resulting in shortness of breath, while right-sided 
HF can cause fluid backup into the abdomen and lower ex-
tremities causing edema.4 Heart failure can also be classified 
as systolic or diastolic. Systolic HF, also known as HF with 
reduced ejection fraction, occurs when the left ventricle can-
not contract with enough force to pump out adequate 
amounts of blood. Diastolic HF, also known as HF with pre-
served ejection fraction, occurs when the left ventricle does 
not fill completely. Many conditions can damage the heart 
resulting in HF including coronary artery disease, myocardial 
infarction, hypertension, obesity, arrhythmias and other 
chronic diseases such as diabetes and dyslipidem-
ia. Following are tables of both the ACCF /AHA Stages of HF 
and the New York Heart Association (NYHA) Functional Clas-
sification from the ACCF /AHA Practice Guidelines.z 
A At high risk for HF with no structural heart disease or symptoms of HF 
8 Structural heart disease without symptoms of HF 
c Structural heart disease with prior or current symptoms of HF 
D Refractory HF requiring specialized interventions 
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Table 2. NYHA Functional Classicfication.2 
NYHA Functional Classification 
I No limitation of physical activity. Ordinary physical activity does not cause HF symptoms 
II Slight limitation of physical activity. Comfortable at rest, but ordinary physical activi ty results in HF symptoms. 
III Marked limitation of physical activity. Comfortable at rest, but less than 
ordinary activity causes HF symptoms. 
IV Unable to carry on any physical activity without symptoms of HF, or 
experience HF symptoms at rest. 
Adapted from Table 4 in the 2013 ACCF/AHA Guideline for the Management of heart failure: a report of the American 
College of Cardiology Foundation/ American Heart Association Task force on practice guidelines. Circ. 2013; 128: e248. 
With numerous possible causes of HF, it can be difficult to 
diagnose. A compilation of data from a patient's medical his-
tory, physical examination and chest radiograph along with 
the presence of indicating symptoms and elevated filling 
pressures are used when diagnosing HF.3 Symptoms a 
patient with HF may experience include dyspnea at rest or 
during exertion, fatigue or weakness, edema in the lower 
extremities, tachycardia, chest pain or palpitations.2.4 When a 
patient presents with these symptoms, a family history as 
well as serial assessments of weight, jugular venous pressure 
and vital signs should be obtained.2 Risk factors are also tak-
en into consideration and include conditions that can dam-
age the heart muscle. These risk factors include sleep apnea, 
viral infections, obesity, alcohol or tobacco use and use of the 
diabetes medications rosiglitazone and pioglitazone, which 
can increase edema and worsen HF.4 Many diagnostic tests 
are used to identify the causative conditions or risk factors of 
HF. One test used to distinguish between systolic and dias-
tolic HF is an echocardiogram, which measures the ejection 
fraction and produces a video image of the heart to show 
how well it is pumping blood. 
Hospitalization for treatment intensification is usually 
required for periodic exacerbations of HF.3 Almost 1 million 
hospitalizations for HF occur each year and it is the most fre-
quent cause for hospitalization of patients over 65 years of 
age. Readmission rates of HF patients <..;e 25 percent within 
30 days of initial hospitalization and can reach up to SO per-
cent within six months.2,3 Both initial hospitalization and re-
admission rates for HF patients continue to rise.3 It is difficult 
to establish a robust risk model for readmission because 
there are many factors to consider that vary from patient to 
patient. 5 There are, however, some clinical predictors for 
readmission. If levels of cardiac biomarkers (such as natriu-
retic peptides and cardiac troponins) remain high at dis-
charge, readmission is likely.2.s Worsening renal function 
during the course of hospitalization for HF is a strong predic-
tor ofreadmission.5 Having lower hospital readmission rates 
would improve the patient's quality of life and also benefit 
the hospital financially. New treatment options to help re-
duce hospital readmission rates are needed. One new option 
is LCZ696, which targets the renin-angiotensin-aldosterone 
system. 
Pharmacology 
In the renin-angiotensin-aldosterone system (also known as 
RAAS), renin from the kidney is responsible for the rate 
limiting step, which is the conversion of angiotensinogen. to 
angiotensin I (ANG 1).6 From this point, ANG I is converted to 
angiotensin II (ANG II) via the angiotensin converting 
enzyme (ACE), which is produced in the lung. Eventually, 
ANG II binds to the angiotensin type 1 receptor (ATl) as seen 
in Figure lA. 
Figure 1A. Renin-Angiotensin-Aldosterone System.6 
Angiotensinogen 











Type 1 Receptor 
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Once ANG II binds to its receptor, different areas of the body 
are affected, including the cardiovascular system, sympathet-
ic nervous system and pituitary gland.6 In general, ANG II 
promotes cell growth and proliferation, inflammatory re-
sponse and oxidative stress. In the cardiovascular system, 
ANG II causes vasoconstriction, which leads to an increase in 
blood pressure and cardiac contractility. This can lead to vas-
cular and cardiac hypertrophy. As ANG II travels to the ad-
renal cortex, it facilitates aldosterone secretion which helps 
regulate sodium and potassium balance. These two electro-
lytes ultimately influence the extracellular volume. With al-
dosterone release, more sodium and water is reabsorbed in 
the distal convoluted tubule and collecting duct. This process 
promotes the excretion of potassium. ANG II also activates 
the sympathetic nervous system, which promotes vasocon-
striction and increases blood pressure. Furthermore, ANG II 
increases vasopressin, also known as antidiuretic hormone 
(ADH), which is released from the pituitary gland and in-
creases water reabsorption. Lastly, while ANG II is activating 
different systems, it also inhibits the atrial natriuretic pep-
tide (ANP) and nitric oxide. When ANP and nitric oxide are 
inhibited, the body's natural way of decreasing renin and 
promoting vasodilation is prevented. 
Since ANG II affects many locations in the body (especially 
the heart), angiotensin II receptor blockers (ARB) are im-
portant in patients with HF. 7 As seen in Figure lB, the 
mechanism of action is selective inhibition of ANG II by com-
petitive antagonism of the ANG II receptors, more specifically 
the ATl receptor. When ANG II is blocked from attaching to 
the receptor, the actions mediated by ATl receptors are in-
hibited.6 This leads to a reduction in blood pressure by de-
creasing the systemic vascular resistance. The sympathetic 
nervous system activity is reduced as well. There is an inhibi-
tion of aldosterone release from the adrenal gland and, 
therefore, less sodium is reabsorbed when ANG II cannot 
bind to the ATl receptor. While the RAAS is working, the na-
triuretic peptides system maintains cardiovascular homeo-
stasis such as the vascular tone, cardiovascular remodeling 
and fluid regulation.a The natriuretic peptides system is the 
body's natural defense to overactive RAAS or sympathetic 
nervous system. This system consists of three peptides: ANP, 
B-type natriuretic peptide (BNP) and C-type natriuretic peptide 
(CNP). Atrial natriuretic peptide is made in the atria and re-
sponds to atrial distention while BNP is produced in the ven-
tricular myocytes and responds to volume overload. 
C-type natriuretic peptide is secreted from the vascular 
endothelium and responds to cytokines. Overall, the natriuretic 
peptides system decreases the release of renin and 
aldosterone, which leads to the suppression of RAAS. Due to 
the suppression of RAAS, the blood pressure and blood volume 
are decreased. While the sympathetic nervous system activity 
is inhibited, the parasympathetic nerve activity increases. 
When natriuretic peptides are released, the opposite effects of 
sympathetic nervous system and RAAS occurs such as vasodila-
tion and decrease in renin secretion (see Figure 2A). 
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Neprilysin (NEP) is an enzyme that degrades the natriuretic 
peptides specifically ANP and CNP.a In addition, NEP de-
grades ANG II, bradykinin and substance P. Bradykinin and 
substance P are vasoactive peptides and are responsible for 
vasodilation. One of the treatments for HF is NEP inhibitors, 
as shown in Figure 2B, which increase natriuretic peptides 
and allow more vasodilation to occur. Since ANG II degrada-
tion is also inhibited, there can be an increase in vasocon-
striction. Therefore, NEP inhibitors depend on the balance 
between the vasoconstrictor and vasodilator effects. 
The angiotensin receptor neprilysin inhibitor (ARNI) may 
serve as a novel treatment option for HF management and is 
currently in clinical trials.9 This drug is currently called 
LCZ696 and must be taken orally in order to become activat-
ed. As seen in Figure 3, once LCZ696 is in the body, it dissoci-
ates into valsartan and Sacubitril (AHU377), which is an ARB 
and a prodrug, respectively. Sacubitril (AHU377) is enzymat-
ically cleaved into LBQ657, which is the active form of the 
neprilysin inhibitor. While LBQ657 is inhibiting neprilysin, 
the valsartan blocks the angiotensin type 1 receptor. Since 
NEP inhibitors are dependent on the balance between the 
vasoconstrictor and vasodilator effects, the valsartan blocks 
any of the vasoconstrictor effects while the vasodilator 
effects are activated. 
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Figure 28. Site of Action of Neprilysin Inhibitors.a Figure 2A. Role of Natriuretic Peptide Hormones.a 
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ANP=atrial natriuretic peptide; BNP=B-type natriuretic peptide; CNP=C-type natriuretic peptide 
Treating HF solely through the means of increasing NEP ap-
pears to be therapeutically insufficient. The ASCEND (Acute 
Study of Clinical Effectiveness of Nesiritide in Decompen-
sated HF) trial assessed nesiritide's role in the prevention of 
rehospitalizations and improvements of dyspnea symptoms 
in HF patients.to As a double-blind, placebo-controlled trial, 
7,141 patients who were hospitalized with acute HF were 
randomly assigned to either nesiritide (recombinant natriu-
retic peptide) or placebo for 24 to 168 hours. Nesiritide 
slightly improved symptomatic dyspnea at six hours 
(P=0.03) and 24 hours (P=0.007) compared to placebo. How-
ever, there was no significant difference in 30-day mortality 
rate (3.6 percent with nesiritide versus 4.0 percent with pla-
cebo; absolute difference of -0.4 percentage points; 95 per-
cent confidence interval, -1.3 to 0.5) or rates of worsening 
renal function, as defined by greater than 25 percent de-
crease in estimated glomerular filtration rate (GFR). Addi-
tionally, nesiritide was associated with increased rates of 
hypotension. Thus, the use of nesiritide should not be the 
standard treatment for HF patients. Similarly, ecadotril, a 
NEP inhibitor, showed little to no improvements in HF symp-
toms and quality oflife in a placebo-controlled trial including 
279 patients.11 Patients on ecadotril showed no difference in 
the six minute walk test (6MWT) compared to placebo pa-
tients. The 6MWT is an outcome measure typically utilized in 
clinical trials to assess the efficacy of HF treatments. Lastly, 
ecadotril is not frequently used in practice due to its serious 
side effect profile (aplastic anemia at higher doses). Candox-
atril, another NEP inhibitor, was tested in 11 healthy men 
and did not demonstrate a promising therapeutic option. 12 
Although central venous pressure was reduced, systolic pres-
sure was increased, most likely due to increased levels of 
epinephrine and endothelin. 
Omapatrilat was the first combination drug manufactured to 
target both neprilysin and ACE. The OVERTURE (Omapatrilat 
Versus Enalapril Randomized Trial of Utility in Reducing 
Events) trial compared its efficacy to an ACE-inhibitor 
(enalapril) in a randomized, double-blind trial of 5,770 pa-
tients.13 The omapatrilat group demonstrated a 9 percent 
lower risk of cardiovascular death or hospitalization 
(P=O .024) and a 6 percent lower risk of mortality. (P=0.339). 
Although showing much promise, omapatrilat does not 
demonstrate a definite clinical superiority over enalapril in 
reducing a primary clinical event (death and rehospitaliza-
tion). Omapatrilat was shown to have a higher occurrence of 
angioedema which led to its withdrawal from the market. 
Angioedema most likely resulted due to increased plasma 
concentrations of bradykinin. Bradykinin induces vasodila-
tion and vascular permeability. As a result, angiotensin 
receptor blockers (ARBs) were further studied as a combina-
tion product due to a decreased risk of angioedema. 
LCZ696 is the first combined drug to incorporate inhibition 
of neprilysin and angiotensin receptor blockade. It was ex-
tensively studied in HF with HFpEF and HF with HFrEF pa-
tients.14.ts The PARAMOUNT (Prospective Comparison of 
ARNI with ARB on Management of HF with Preserved 
Ejection Fraction) trial was a randomized, parallel group, 
double-blind study which compared LCZ696's therapeutic 
effectiveness to valsartan monotherapy.1s Patients included 
in this study were required to be classified as a NYHA class II 
to III (see Table 1 and Table 2), have a left ventricular 
ejection fraction greater than 45 percent and have an 
N-terminal B-type natriuretic peptide (NT-proBNP; marker 
of ventricular wall stress) greater than 400 pg/ml. Change in 
serum NT-proBNP concentrations 12 weeks from baseline 
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was the primary endpoint in this study. Patients were then 
followed through 36 weeks for additional endpoints. At the 
start of the trial, 308 patients were randomized to LCZ696 
200 mg twice daily or valsartan 160 mg twice daily (both 
doses were bioequivalent). After 12 weeks, NT-proBNP lev-
els were significantly reduced in the LCZ696 group com-
pared to valsartan group (p=0.005). At 36 weeks, LCZ696 
patients had better improvements in left atrial size, greater 
improvements in NYHA class, and greater reductions in 
blood pressure. Additionally, GFR was higher in patients re-
ceiving LCZ696 compared to patients receiving valsartan. 
Further prospective studies need to be conducted in order to 
assess whether these observed effects would translate to 
improved patient outcomes. Future experiments should in-
crease the duration of follow-up in order see the long-term 
clinical benefits of LCZ696. 
In the PARADIGM-HF (Prospective Comparison of ARNI with 
ACE! to Determine Impact on Global Mortality and Morbidity 
in HF) trial, 8,442 patients were randomly assigned to re-
ceive either LCZ696 (200 mg twice daily) or enalapril (10 mg 
twice daily).15 Patients were required to be classified as a 
NYHA class II to III, have a left ventricular ejection fraction of 
less than 40 percent and have a NT-proBNP level of greater 
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than 600 pg/ml. Other inclusion criteria were GFR greater 
than 30 ml/min/1.73 m2, systolic blood pressure greater 
than 95 mmHg and potassium less than 5.4 mmolfl. The pri-
mary endpoint was the composite of death from cardiovascu-
lar causes or hospitalizations from HF. There were 558 
deaths from cardiovascular causes in the LCZ696 patients 
and 693 deaths in the enalapril patients. LCZ696 was found 
to reduce hospitalizations by 21 percent and decrease symp-
toms and physical limitations of HF (P= 0.001). This study 
ended early due to the clear and "overwhelming benefits" of 
LCZ696 over enalapril. 
From these clinical trials, LCZ696 has consistently demon-
strated its clinical efficacy via improvements in many cardiac 
parameters. Dual inhibition of neprilysin and the renin-
angiotensin-aldosterone system provides a new method to 
effectively and safely treat HF patients. 
Pharmacist Role 
Although LCZ696 has been well-tolerated by patients overall, 
it is still imperative that pharmacists counsel patients on the 
potential side effects and the importance of adherence to 
their medication regimen. A potential adverse reaction is 
hypotension, so patients should be consulted about the 
symptoms of low blood pressure including dizziness; synco-
pe; blurred vision; nausea; cold, clammy, pale skin and rapid, 
shallow breathing.9 Angioedema rarely occurred in trials, 
but patients should be educated on signs and symptoms 
so they may seek care early to avoid airway compro-
mise. Medication noncompliance is a risk factor for hospital 
admission. Counseling on the importance of HF medication 
adherence helps the patients to understand why they are 
taking the medication because they may not always physical-
ly feel an impact.2 
It is important that pharmacists educate their patients not 
only about the medications they are taking but also about 
their disease states and how lifestyle modifications can im-
pact them. Stressing the benefits of weekly physical activity, 
dietary sodium and fluid restriction and staying within a 
healthy weight to patients can help reduce the incidence of 
HF exacerbations.2 Encouraging patients to find a support 
system has been shown to reduce hospitalizations and mor-
tality because patients are more likely to adhere to their 
treatment regimen and live a healthier lifestyle. Being the 
most accessible health care providers to some patients, phar-
macists should follow-up with recently discharged HF 
patients for education to prevent readmission and lower HF 
exacerbations.s 
Conclusion/Outlook for the Future 
Each year there are many new cases of HF, a disease respon-
sible for increased hospital readmission rates. Currently, 
ACE-I are used to control HF, which is insufficient alone. 
A novel drug, LCZ696, may be an alternative to the current 
first line therapies of ACE-I and ARB for HF, specifically 
HFrEF. LCZ696 is an angiotensin receptor neprilysin inhibi-
tor, which inhibits neprilysin through LBQ657 and blocks the 
ATl receptor through valsartan.9 Overall, LCZ696 had less 
cardiovascular mortality and HF hospitalizations compared 
to other monotherapies. In addition, patients tolerated this 
drug better than omapatrilat, which had higher incidence of 
angioedema.13 In comparison to enalapril, LCZ696 had less 
hospitalizations and less physical limitations in patients.1s 
Currently, LCZ696 has been studied in patients with HFpEF; 
however, longer follow-up is needed in order to determine 
long-term effects of LCZ696.14 Pharmacists should be antici-
pating the use of this novel drug and educate patients on 
ways to improve their quality of life through medications and 
lifestyle modifications. Overall, pharmacists can help reduce 
hospital readmission and HF exacerbations through im-
proved patient education.s 
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